Biotech News

Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

Kura Oncology (KURA)Kura OncologyEarnings

– KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market – – Eight abstracts

Related news

Kura Oncology

Precision Oncology Company Kura Oncology develops and commercializes small-molecule therapies for genetically defined cancers. Its portfolio focuses on menin inhibition in hematologic malignancies and farnesyl-transferase inhibition in solid tumors. KOMZIFTI KOMZIFTI, or ziftomenib, is an FDA-approved oral menin inhibitor for adults with...

Recent company news

Stock data

Close
7.35 USD
Market cap
796.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States